ANALYSIS: White labelling is a global phenomenon, but are there winners and losers?
Shoeshine: Thwarted by underinvestment, can it come back from the brink?
Shoeshine: Glass Lewis thinks Infratil has a diversity problem.
Rocks thrown over passive and active approaches.
Analysis: Will the cutbacks bear fruit?
Analysis: Australian pharmaceuticals distribution is low margin, highly competitive and heavily regulated.
Analysis: Has the company's turnaround strategy paid off?